β2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk.

Bojing LiuPer SvenningssonJonas F LudvigssonCecilia LundholmJohan WallinHenrik LarssonArvid SjölanderDylan M WilliamsNancy L PedersenKarin Wirdefeldt

Published in: Annals of neurology (2023)

Overall, our data do not support inverse associations between β2AR agonists, montelukast, and PD. The prospect of lower PD incidence with high-dose montelukast exposure warrants further investigation, especially with adjustment for high-quality data on smoking. ANN NEUROL 2023.

Keyphrases

parkinson disease
high dose
deep brain stimulation
electronic health record
big data
low dose
risk factors
stem cell transplantation
neural network